Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
  • Users Online: 5343
  • Home
  • Print this page
  • Email this page

   Table of Contents      
LETTER TO THE EDITOR
Year : 2013  |  Volume : 61  |  Issue : 7  |  Page : 367-368

Intralesional bleomycin injection for periocular capillary hemangiomas


Department of Ophthalmology, University College of Medical Sciences and G.T.B. Hospital, Delhi, India

Date of Web Publication30-Jul-2013

Correspondence Address:
V P Gupta
275, Ground Floor, GaganVihar, Delhi - 110 051
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0301-4738.115790

Rights and Permissions

How to cite this article:
Gupta V P, Gupta P. Intralesional bleomycin injection for periocular capillary hemangiomas. Indian J Ophthalmol 2013;61:367-8

How to cite this URL:
Gupta V P, Gupta P. Intralesional bleomycin injection for periocular capillary hemangiomas. Indian J Ophthalmol [serial online] 2013 [cited 2020 Feb 26];61:367-8. Available from: http://www.ijo.in/text.asp?2013/61/7/367/115790

Dear Editor,

We read the article by Smit and Meyer [1] with keen interest. We wish to express the following comments:

Intralesional bleomycin injection (IBI) is a newer form of therapy for capillary hemangioma with encouraging results. [1],[2],[3],[4],[5] IBI was used for the first time for complicated cutaneous hemangiomas. [2] Experience with IBI for periocular capillary hemangiomas is very limited.

Authors diagnosed capillary hemangioma by clinical examination only. [1] We believe clinical evaluation should have been combined with ultrasonography or magnetic resonance imaging or color doppler to differentiate hemangioma from vascular malformation. [3],[4],[5] Color doppler is also of immense utility during follow-up in detecting size, color, and blood flow changes after IBIs. Blood flow in capillary hemangioma declines after four to five IBIs; blood flow signal disappears earlier than color (usually after five to six IBIs for a lesion diameter less than 4 cm). [3],[4]

Authors discontinued therapy after administering nine IBIs in case one and after five IBIs in case two. [1] We appreciate the result with respect to opening of eye and increase in vertical height of palpebral fissure which might be adequate to prevent stimulus deprivation amblyopia, however, post IBI Figure 2 and Figure 4 clearly depict significant residual capillary hemangioma covering the forehead, nose, upper lip, and even left upper eyelid of case 1 and forehead, nose and right upper eyelid of case 2 respectively. [1] We believe the treatment should not have been stopped at this stage. The hemangioma involving forehead, nose, and lips still required intralesional bleomycin. It has been suggested that the interval of injection should be 3-4 weeks with total times lesser than 7 times during one therapeutic period. [3],[4] Another therapeutic period may be started 3 months later if further treatment was necessary. The total quantity of bleomycin for a child should be less than 40 mg in one treatment periods. [3],[4] Luo and Jhao reported very large series of 82 cases of infantile hemangiomas which involuted completely after treatment with the sclerosing mixture composed of 2% lidocaine, 5 mg dexamethasone and 8 mg bleomycin A5 and also used oral prednisolone (2-5 mg/kg every other day). [3],[4] Combination of dexamethasone with bleomycin as well as oral prednisolone has been advocated to treat effectively the patients at proliferating stage observed in the 3 rd and 6 th month in many cases of infantile hemangioma and also to circumvent the dose restriction of bleomycin i.e., the drug quantity given in one time may be deficient for big hemangioma(>4 cm). [3],[4]

Authors suggest use of bleomycin in the treatment of eyelid hemangiomas where conventional modalities have been unsuccessful or where treatment with beta-blockers may be contraindicated. [1] Many investigators recommend oral propranolol as the first line of therapy for infantile hemangioma. [6] Readers would be interested to know why authors [1] did not treat these cases with oral propranolol as first line therapy.

 
  References Top

1.
Smit DP, Meyer D. Intralesional bleomycin for the treatment of periocular capillary hemangiomas. Indian J Ophthalmol 2012;60:326-8.  Back to cited text no. 1
[PUBMED]  Medknow Journal  
2.
Sarihan H, Mocan H, Yildiz K, Abes M, Akyazici R. A new treatment with bleomycin for complicated cutaneous hemangioma in children. Eur J Pediatr Surg 1997;7:158-62.  Back to cited text no. 2
[PUBMED]    
3.
Luo QF, Zhao FY. The effects of Bleomycin A5 on infantile maxillofacial haemangioma. Head Face Med 2011;7:11.  Back to cited text no. 3
[PUBMED]    
4.
Luo Q, Zhao F. How to use bleomycin A5 for infantile maxillofacial haemangiomas: Clinical evaluation of 82 consecutive cases. J Craniomaxillofac Surg 2011;39:482-6.  Back to cited text no. 4
[PUBMED]    
5.
Yang Y, Sun M, Cheng X, Hu X, Zhang P, Ma Q, et al. Bleomycin A5 plus dexamethasone for control of growth in infantile parotid hemangiomas. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009;108:62-9.  Back to cited text no. 5
[PUBMED]    
6.
Holmes WJ, Mishra A, Gorst C, Liew SH. Propranolol as first-line treatment for rapidly proliferating infantile haemangiomas. J Plast Reconstr Aesthet Surg 2011;64:445-51.  Back to cited text no. 6
[PUBMED]    




 

Top
 
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
References

 Article Access Statistics
    Viewed816    
    Printed5    
    Emailed0    
    PDF Downloaded127    
    Comments [Add]    

Recommend this journal